Clinical trials: Immunoglobulin
Gastrointestinal Microbiome, Immunoglobulin A
The Effect of Maternal Dadiah Supplementation During Pregnancy on Child Growth and Gastrointestinal Health Outcomes
The aim of our study is to assess the effect of giving dadiah as a supplement to pregnant women on improving the growth and digestive health of children.
- Conditions
- Gastrointestinal Microbiome, Immunoglobulin A, Growth; Stunting, Nutritional
- Trial name
- NCT05140928
- Testing
- Dadiah Pudding, Pudding without Dadiah
- Where
- Indonesia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Andalas University
Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood.
- Trial name
- NCT05132621
- Testing
- Smear
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Medical University of Warsaw
Bronchiectasis, Immunoglobulin Subclass Deficiency
Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis
Bronchiectasis is a common chronic lung condition where patients have permanent airways damage leading to daily symptoms of cough, sputum production and recurrent respiratory tract infections.
- Trial name
- NCT03737617
- Testing
- Cuvitru 20 % Injectable Solution
- Where
- United Kingdom
- Sponsor
- University of Edinburgh
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Amyloidosis
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
- Trial name
- MRD (NCT02716103)
- Testing
- blood collection, bone marrow collection
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boston Medical Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
IgG4-related Disease
Safety and Efficacy of Abatacept in IgG4-Related Disease
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study.
- Trial name
- NCT03669861
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Amyloidosis
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.
- Trial name
- NCT00981708
- Testing
- Lenalidomide, Dexamethasone and Cyclophosphamide
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- University of Athens
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Amyloidosis
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis.
- Trial name
- CATALYST (NCT02545907)
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Convalescent Plasma, Covid19
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt
One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from individuals who have recovered from COVID-19 (Refs. 1-4).
- Conditions
- Convalescent Plasma, Covid19, Immunoglobulins, Plasma
- Trial name
- NCT04816942
- Testing
- Convalescent Plasma
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ministry of Health and Population, Egypt
Amyloidosis; Systemic
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
Survival of intermediate and high-risk primary light chain amyloidosis (pAL) remains poor due to high mortality within 3-6 months of diagnosis.
- Trial name
- NCT03401372
- Testing
- Doxycycline, Bortezomib, Cyclophosphamide
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Jian Li
IgG4-related Disease
Characterizing IgG4-RD With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it might be more sensitive than FDG…
- Trial name
- NCT04125511
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
IgG4-related Disease
Belimumab Treatment for IgG4-related Disease
Even though glucocorticoid is the current first line medication for IgG4-RD, it is well accepted in the field that excessive dosage of GC, especially accumulative dosage, is associated with increasing organ damage.
- Trial name
- NCT04660565
- Testing
- Prednisone and Belimumab, Prednisone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Immunoglobulin Light-Chain Amyloidosis
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Research Objective:At present, there is no standard therapeutic regimen for monoclonal immunoglobulin light chain (AL) amyloidosis in the world.
- Trial name
- NCT04612582
- Testing
- Thalidomide, Cyclophosphamide
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
AL Amyloidosis
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
This study seeks to enroll patients with AL amyloidosis, for whom treatment with one of the standard melphalan chemotherapy-based regimens is either not recommended or is not their preference.
- Trial name
- NCT01570387
- Testing
- Pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Medical Center